Article info

Download PDFPDF

The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma

Authors

  1. Correspondence to Dr Brian Slomovitz, Gynecologic Oncology, Mount Sinai Medical Center, Miami, FL 33140, USA; bslomovitz{at}gog.org
View Full Text

Citation

Ray-Coquard I, Monk BJ, Lorusso D, et al
The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma

Publication history

  • Received June 14, 2023
  • Accepted August 29, 2023
  • First published October 31, 2023.
Online issue publication 
December 04, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.